Truist Securities stays Buy on Agios Pharma (AGIO) as co seeks accelerated approval for mitapivat

March 31, 2026 8:33 AM

Truist Securities analyst Greg Renza reiterated a Buy rating and $39.00 price target on Agios Pharma (NASDAQ: AGIO)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found